Drug LitigationLexapro Agent Present in Breast Milk

December 15, 2011

In recent years, Lexapro patients have become increasingly aware of some of the risks associated with escitalopram, the active agent in Lexapro. For instance, thanks to warnings by the Food and Drug Administration (FDA) and studies published in medical journals like the New England Journal of Medicine, women who are pregnant or may become pregnant understand that continuing their prescription to Lexapro and other antidepressants during their pregnancy will significantly increase the probability that their child will develop birth defects such as persistent pulmonary hypertension (PPHN).

 

Unfortunately, what many patients don’t realize is that the risks associated with Lexapro (escitalopram) don’t stop with birth. For women who breastfeed their children, significant amounts of the chemicals present in Lexapro will be communicated to their infant through the breast milk. The same kinds of concerns – such as PPHN and neonatal abstinence syndrome (NAS) – remain!

 

Want to know more information about the risks of Lexapro (escitalopram)? Worried that your child’s birth defects or slow development might be related to your antidepressant medication? Talk to the attorneys and counselors at Nachawati Law Group today. We know how to fight for you because we’ve fought for so many other victims of dangerous drugs. For a free consultation, call us at 1.866.545.8364 or email [email protected]

———

About Nachawati Law Group
Nachawati Law Group represents parties in mass tort litigation, businesses and governmental entities in contingent litigation, and individuals in complex personal injury litigation. For more information, visit contact [email protected] or call 214-890-0711.

https://ntrial.com/ntrial/wp-content/uploads/Nachawati-Law-logo-White-2-160x25.png

©2025 Nachawati Law Group           Terms and Conditions | Privacy Policy